News

Hosted on MSN26d
Cytokinetics rises as Edgewise posts mid-stage trial data for heart disorder therapy
Edgewise (NASDAQ:EWTX) shed ~25% in the premarket after the readout, which coincided with a $200M capital raise announced by the company.Citing data from its Phase 2 CIRRUS trial, EWTX said that ...
Nasdaq26d
Edgewise Therapeutics Announces Pricing of $200 Million Underwritten Offering of Common Stock
BOULDER, Colo., April 2, 2025 /PRNewswire/ -- Edgewise Therapeutics, Inc. (NASDAQ: EWTX), a leading muscle disease biopharmaceutical company, today announced the pricing of an underwritten ...
Business Wire1mon
Edgewise Therapeutics to Present on Sevasemten for the Treatment of Becker Muscular Dystrophy at the 2025 MDA Clinical and Scientific Conference
BOULDER, Colo.--(BUSINESS WIRE)--Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced that the company will present data on sevasemten ...